(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
(IN BRIEF) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has received accelerated approval in China for patients with advanced NSCLC carrying HER2 mutations who have progressed after prior therapy. The approval is supported by Beamion-LUNG 1 data, which showed a 71% objective … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AACR 2025, Beamion-LUNG 1, Beamion-LUNG 2, Boehringer Ingelheim, breakthrough therapy designation, CHINA, HER2 mutations, HERNEXEOS, New England Journal of Medicine, NMPA approval, non-small cell lung cancer, NSCLC, oncology, partnership, Shashank Deshpande, targeted therapy, tyrosine kinase inhibitor, Wu Yilong, zongertinib
(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged autoimmune disease, B cell depletion, BAFF-R inhibition, biopharmaceuticals, clinical trial results, ESSDAI, Fast Track Designation, ianalumab, immunology research, MorphoSys AG, NEPTUNUS-1, NEPTUNUS-2, Novartis, Shreeram Aradhye, Sjögren’s disease, systemic autoimmune disorder, targeted therapy, US FDA, VAY736
(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADAURA trial, ADAURA2, adjuvant therapy, AstraZeneca, cancer survival, chemotherapy, EGFRm NSCLC, EMA, FDA, FLAURA2 trial, global clinical trial, LAURA trial, lung cancer treatment, NeoADAURA, non-small cell lung cancer, oncology, osimertinib, overall survival, Pasi A. Jänne, pemetrexed, platinum-based treatment, progression-free survival, Susan Galbraith, Tagrisso, targeted therapy
(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher
(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged abiraterone, AKT inhibitor, biomarkers, clinical trial, genetic markers, Institute of Cancer Research London, ipatasertib, IPATential150 trial, metastatic castration-resistant prostate cancer mCRPC, overall survival, personalized medicine, PIK3CA/AKT1/PTEN pathway, Professor Johann de Bono, PTEN gene, Roche, sequencing techniques, synthetic lethality, targeted therapy, UK patients
(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs). This targeted therapy promises to improve survival rates by precisely attacking cancer cells while … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged ADC, antibody-drug conjugates, cancer treatment, chemotherapy, colon cancer, Finsen Laboratory, human clinical trials, immune system, Lars Henning Engelholm, pancreatic cancer, pharmaceutical research, precision medicine, Rigshospitalet, sarcoma, Science Advances, survival rates, targeted therapy, triple-negative breast cancer, University of Copenhagen
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?